Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359460 | 1.00 | BTK (0.50) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359117 | 0.94 | BTK (0.44) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359114 | 0.94 | BTK (0.44) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359784 | 0.92 | BTK (0.49) | BTKTP53RXFP1 | |
| SCHEMBL20359782 | 0.92 | BTK (0.49) | BTKTP53RXFP1 | |
| SCHEMBL20365214 | 0.92 | BTK (0.43) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359363 | 0.86 | BTK (0.47) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359362 | 0.86 | BTK (0.47) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359309 | 0.85 | BTK (0.44) | BTKTP53RXFP1MEN1NPC1 | |
| SCHEMBL20359307 | 0.85 | BTK (0.44) | BTKTP53RXFP1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | BTK 1/4885TP53 907/4885RXFP1 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.